Our monthly roundup of ‘people on the move’ in Canada’s life science and biotech sectors.
Jubilant DraxImage Inc. has named James Kaufman as director Marketing, PET Products effective immediately. Reporting, to Michael Rossi, president, Jubilant DraxImage, Kaufman will be responsible for leading the development and commercialization of the company’s cardiovascular PET products. Kaufman joins Jubilant DraxImage from GE Healthcare where he served as the Global Product leader, Life Sciences-Core Imaging.
Dr. Andres A. Gutierrez has joined Oncolytics Biotech® Inc. as the company’s new chief medical officer. He replaces Dr. Alan Tuchman, who will remain with Oncolytics in his new role of chief neuro oncology research officer. Dr. Gutierrez is board certified in internal medicine and completed a fellowship in medical oncology. Most recently he has held progressively senior clinical development positions designing and implementing both early and later-stage oncology clinical studies at a range of U.S. and European companies including Sellas Life Sciences Group, Bristol-Myers Squibb, Sunesis Pharmaceuticals Inc, Biomarin Pharmaceutical Inc, Proteolix, and Oculus Innovative Sciences. Prior to that, he held a series of academic and consulting positions. He has also authored and co-authored more than 90 peer-reviewed publications and abstracts and presented at numerous conferences over his 32 year career.
Stephen L. Lemieux, chief financial officer and secretary of Cipher Pharmaceuticals Inc., has been named the company’s new interim CEO, replacing Shawn O’Brien, who is pursuing other opportunities. Cipher has also commenced the formal search process for a new CEO. Prior to joining Cipher, Lemieux served as vice president and chief financial officer of Nuvo Pharmaceuticals. Before this he held multiple senior financial positions, including corporate controller at Martinrea International Inc., a Tier One automotive supplier, and assistant controller at Magna Powertrain. He also worked for Ernst & Young performing audit, restructuring and accounting work for its clients. He is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting from the University of Toronto.
Ms. Lota S. Zoth, CPA, has joined Zymeworks Inc.‘s board of directors. Zoth brings extensive experience to the board, serving in senior financial and operational roles at a variety of companies across various industries over her 34-year career, including as chief financial officer for MedImmune before its acquisition by AstraZeneca in 2007. She has also served as a member of multiple public and private company boards over the past decade in the biopharmaceutical industry. Concurrent with Ms. Zoth’s appointment, Amos Michelson will be stepping down as a member of the Board of Directors.
CQDM has added two new members to its board. They are Patrick Wier, senior vice president, In vitro/In vivo Translation Platform at GSK and Jorge Puente, co-founder and managing partner of Pleasanton Pharma Ventures. Wier has worked for GSK for more than 25 years. Prior to becoming senior vice president, In vitro/In vivo Translation Platform, he served as global head of nonclinical safety following his leadership of several component disciplines therein. Puente has had an extensive career in many areas of the pharmaceutical industry since joining 25 years ago. He served most recently as president of the Asia and Canada regions for Pfizer’s oncology unit and was simultaneously the head of Oncology Clinical Development for Pfizer in China. He is now the co-founder and managing partner of Pleasanton Pharma Ventures.
Aspect Biosystems Ltd. announces the appointments of James Hatton and Paul Drohan to its board of directors. Hatton, QC, is a partner at Farris, Vaughan, Wills & Murphy LLP and a director of BC Hydro, the principal electricity utility for the province of British Columbia. He is also the chair of Life Sciences BC and a director of the Central City Foundation. Previously, he was president of The Greater Vancouver Food Bank Society for six years, and remains an honorary life director of that organization. He has formerly served on a number of boards including the board of governors of Royal Roads University and the governing council of the National Research Council of Canada. Drohan is a healthcare senior executive with over 25 years’ experience in the global biopharmaceutical industry. Most recently, he served as president and CEO of LifeSciences BC, and as global senior vice president for Genzyme (a Sanofi Company). He too has served on a number of boards including Genzyme UK & Ireland, BioIndustry Association, and LifeSciences BC.
Innovative Medicines Canada has named Pamela Fralick as its new president, effective immediately. She comes to Innovative Medicines Canada as a proven healthcare leader, with a wealth of experience advancing critical healthcare initiatives and a deep understanding of public policy and organizational management. As the former president and CEO of the Canadian Cancer Society, she led a three-year process of intense transformation, resulting in significant improvements to the operational and governance structures of the organization. Prior to this, she spent five years as president and CEO of the Canadian Healthcare Association, a federation of provincial and territorial hospital and health organizations, as well as six years as CEO of the Canadian Physiotherapy Association. She was chair of the Health Action Lobby (HEAL) and co-chair of the Canadian Coalition for Public Health in the 21st Century (CCPH21). She has also held senior positions with the Canadian Centre on Substance Abuse and Health Canada’s Alcohol and Other Drugs Unit. Ms. Fralick takes over from Elaine Campbell, who has been interim president of Innovative Medicines Canada since June.
Aurinia Pharmaceuticals Inc. has brought Lorin Jeffry “Jeff” Randall on board as a member of the company’s board of directors and chairman of its Audit Committee. Currently, he serves on the boards of directors of Athersys, Inc. where he also serves as Chairman of the Audit and Compensation Committees, and Acorda Therapeutics, Inc. where he serves on the Audit, Compliance and Nominations and Governance Committees. In addition to his current board positions, Randall served on the board of directors of Nanosphere, Inc. from 2008 to 2016, and most recently as Chairman of the Board. From 2004 to 2006, he was senior vice president and CFO of Eximias Pharmaceutical Corporation.
Dr. Alain Beaudet, president of the Canadian Institutes of Health Research (CIHR), has informed the Minister of Health, the Honourable Jane Philpott and the CIHR Governing Council, of his retirement from the public service and CIHR at the end of March 2017. During his tenure at CIHR, Dr. Beaudet has spearheaded a number of innovative and transformative domestic health research initiatives such as Canada’s Strategy for Patient-Oriented Research, and a major reform of CIHR’s open programs and peer review processes. Internationally, he has championed several multilateral research initiatives, notably the Global Alliance for Chronic Diseases (GACD), of which he is currently board chair. The position of president of CIHR is a Governor in Council appointment and as such the CIHR Executive Team will work with the office of the Minister of Health to initiate the process for recruiting Dr. Beaudet’s successor.
The NEOMED Institute announces that Dr. Max Fehlmann is stepping down from his position of CEO of the NEOMED Institute and NEOMED-LABS at the end of the year. He is leaving the organization to join the Cancer Research Society in the role of president and CEO. He will begin his new role effective January 16, 2017. Fehlmann, a senior executive with more than 35 years of experience in management, financing and business development in the public and private sectors, founded the NEOMED Institute, and was its president since 2012. Before NEOMED, he founded the Consortium Québécois pour la Découverte du Médicament (CQDM) in 2008, a public-private non-profit organization financing precompetitive research in drug discovery. He held the position of President and CEO until 2012. Prior to that, Max Fehlmann was President and CEO of Chronogen Inc., a Montreal-based biotechnology company, from 2004 to 2007. Presently, Fehlmann is a member of the Scientific Advisory Board of OncoAge in Nice, France, a member of the Board of Directors of RSSPQ in Montreal, and a member of the Board of Directors of CQDM, Montreal. Donald Olds, the Chairman of the Board of the NEOMED Institute, has been named executive chairman and interim CEO, while Luc Vachon, currently chairman of the board of NEOMED‐LABS, has been appointed interim CEO of NEOMED‐LABS. In addition, Phillipe Walker, chief scientific officer of NEOMED Institute has been named general manager for NEOMED’s R&D programs and Pierre‐Yves Desbiens, VP finance and operations of NEOMED Institute has been named general manager for the NEOMED Campus (building and services).